Bristol Myers Squibb has notched another FDA approval for its blockbuster immunology drug Orencia, this time for preventing acute graft versus host disease in bone marrow and stem cell transplant patients. The decision makes the BMS drug the first one approved for preventing this complication of transplant procedures.
The cash deal brings to Sanofi the Kadmon Holdings drug Rezurock, which the FDA approved in July as a treatment for chronic graft versus host disease. The French pharmaceutical giant will add Rezurock to a lineup of older products marketed globally for transplant procedures.
AI-native tax firm Gelt combines top human tax experts with AI to help physicians and healthcare practices use data-driven tax strategies to lower liabilities, improve profitability, and future-proof their finances.
The San Francisco Bay Area-based company has two programs in clinical development, which aim to provide the benefits of bone marrow transplantation without the potentially fatal complications involved.